Versican and its associated molecules: Potential diagnostic markers for multiple myeloma

Clinica Chimica Acta

Volumn 442, Issue , 2015, Pages 119-124

  Gupta, Nidhi ^a   Khan, Rehan ^a   Kumar, Raman ^a   Kumar, Lalit ^a   Sharma, Alpana ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Diagnostic marker; FAK; Multiple myeloma; Versican; Catenin; 1 Integrin

Indexed keywords

BETA 2 MICROGLOBULIN; BETA CATENIN; BETA1 INTEGRIN; CREATININE; FOCAL ADHESION KINASE; MESSENGER RNA; UREA; VERSICAN; FOCAL ADHESION KINASE 1; PTK2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE MARROW DERIVED MONONUCLEAR CELL; CANCER STAGING; CELL LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; MULTIPLE MYELOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; WESTERN BLOTTING; BLOOD; GENE EXPRESSION REGULATION; GENETICS; INTRACELLULAR SPACE; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTIGENS, CD29; BETA CATENIN; BIOMARKERS, TUMOR; FEMALE; FOCAL ADHESION KINASE 1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SPACE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RNA, MESSENGER; ROC CURVE; VERSICANS;

EID: 84922259348     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.01.012     Document Type: Article

References (33)

1. Palumbo A., Anderson K. Multiple myeloma. N Engl J Med 2011, 364:1046-1060. 10.1056/NEJMra1011442.
2. Ghobrial I.M. Myeloma as a model for the process of metastasis: implications for therapy. Blood 2012, 120:20-30. 10.1182/blood-2012-01-379024.
3. Manier S., Sacco A., Leleu X., Ghobrial I.M., Roccaro A.M. Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol 2012, 2012:157496. 10.1155/2012/157496.
4. Klominek J., Robert K.H., Sundqvist K.G. Chemotaxis and haptotaxis of human malignant mesothelioma cells: effects of fibronectin, laminin, type IV collagen and an autocrine motility factor-like substance. Cancer Res 1993, 53:4376-4382.
5. Wight T.N. Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol 2002, 14:617-623.
6. Du W.W., Yang W., Yee A.J. Roles of versican in cancer biology-tumorigenesis, progression and metastasis. Histol Histopathol 2013, 28:701-703.
7. Du W.W., Fang L., Yang X., et al. The role of versican in modulating breast cancer cell self-renewal. Mol Cancer Res 2013, 11:443-455. 10.1158/1541-7786.MCR-12-0461.
8. Sakko A.J., Ricciardelli C., Mayne K., Tilley W.D., Lebaron R.G., Horsfall D.J. Versican accumulation in human prostatic fibroblast cultures is enhanced by prostate cancer cell-derived transforming growth factor beta1. Cancer Res 2001, 61:926-930.
9. Corral L.L., Corchete L.A., Sarasquete M.E., et al. Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies. Haematologica 2014, 99:1365-1372. 10.3324/haematol.2013.087809.
10. Makatsori E., Lamari F.N., Theocharis A.D., et al. Large matrix proteoglycans, versican and perlecan, are expressed and secreted by human leukemic monocytes. Anticancer Res 2003, 23:3303-3309.
11. Kischel P., Waltregny D., Greffe Y., et al. Identification of stromal proteins overexpressed in nodular sclerosis Hodgkin lymphoma. Proteome Sci 2011, 9:63. 10.1186/1477-5956-9-63.
12. Havre P.A., Dang L.H., Ohnuma K., Iwata S., Morimoto C., Dang N.H. CD26 expression on T-anaplastic large cell lymphoma (ALCL) line Karpas 299 is associated with increased expression of Versican and MT1-MMP and enhanced adhesion. BMC Cancer 2013, 13:517. 10.1186/1471-2407-13-517.
13. Rahmani M., Read J.T., Carthy J.M., McDonald P.C., Wong B.W., Esfandiarei M. Regulation of the versican promoter by the β-catenin-T-cell factor complex in vascular smooth cells. J Biol Chem 2005, 280:13019-13028.
14. Goodwim A.M., D'Amore P.A. Wnt signaling in the vasculature. Angiogenesis 2002, 5:1-9.
15. Rahmani M., Wong B.W., Ang L., et al. Versican: signaling to transcriptional control pathways. Can J Physiol Pharmacol 2006, 84:77-92.
16. Kishimoto J., Burgeson R.E., Morgan B.A. Wnt signaling maintains the hair-inducing activity of the dermal papilla. Genes Dev 2000, 14:1181-1185.
17. Kim Y., Reifenberger G., Lu D., et al. Influencing the Wnt signaling pathway in multiple myeloma. Anticancer Res 2011, 31:725-730.
18. Wang Y.X., Zhang J.H., Gu Z.W. Wnt/β-catenin signal pathway and malignant hematological disease. J Exp Hematol 2009, 17:234-237.
19. Li J., Zhang D.B., Luo S.K., Zhao Y., Huang B.H., Gu J.L. Expression and clinical significance of β-catenin in multiple myeloma. Chin J Cancer 2007, 26:1010-1014.
20. Liang W., Yang C., Qian Y., Fu Q. Effects of short-hairpin RNA- inhibited β-catenin expression on the growth of human multiple myeloma cells in vitro and in vivo. Biochem Biophys Res Commun 2012, 422:681-686. 10.1016/j.bbrc.2012.05.054.
21. Yao H., Ashihara E., Strovel J.W., et al. AV-65, a novel Wnt/β-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse model. Blood Cancer J 2011, 1:e43. 10.1038/bcj.2011.41.
22. Sukhdeo K., Mani M., Zhang Y., et al. Targeting the β-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci 2007, 104:7516-7521.
23. Wu Y.J., Lapierre D., Wu J., Yee A.J., Yang B.B. The interactions of versican with its binding partners. Cell Res 2005, 15:483-494.
24. Jensen G.S., Belch A.R., Mant M.J., Ruether B.A., Yacyshyn B.R., Pilarski L.M. Expression of multiple beta 1 integrins on circulating monoclonal B cells in patients with multiple myeloma. Am J Hematol 1993, 43:29-36.
25. Tatsumi T., Shimazaki C., Goto H., et al. Expression of adhesion molecules on myeloma cells. Jpn J Cancer Res 1996, 87:837-842.
26. Wang S.Y., Hao H.L., Deng K., et al. Expression levels of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and focal adhesion kinase in patients with multiple myeloma and their relationship to clinical stage and extramedullary infiltration. Leuk Lymphoma 2012, 53:1162-1168. 10.3109/10428194.2011.647311.
27. Wang S., Cheng Z., Yang X., et al. Effect of wild type PTEN gene on proliferation and invasion of multiple myeloma. Int J Hematol 2010, 92:83-94. 10.1007/s12185-010-0604-y.
28. Romano A., Conticello C., Cavalli M., et al. Immunological dysregulation in multiple myeloma microenvironment. Biomed Res Int 2014, 2014:198539. 10.1155/2014/198539.
29. Khan R., Gupta N., Kumar R., Sharma M., Kumar L., Sharma A. Augmented expression of urokinase plasminogen activator and extracellular matrix proteins associates with multiple myeloma progression. Clin Exp Metastasis 2014, 31:585-593. 10.1007/s10585-014-9652-7.
30. Slany A., Haudek-Prinz V., Meshcheryakova A., et al. Extracellular matrix remodeling by bone marrow fibroblast-like cells correlates with disease progression in multiple myeloma. J Proteome Res 2014, 13:844-854. 10.1021/pr400881p.
31. Rahmani M., McDonald P.C., Wong B.W., McManus B.M. Transplant vascular disease: role of lipids and proteoglycans. Can J Cardiol 2004, 20:58-65.
32. Hope C., Ollar S.J., Heninger E., Hebron E., Jensen J.L., Kim J. TPL2 kinase regulates the inflammatory milieu of the myeloma niche. Blood 2014, 123:3305-3315. 10.1182/blood-2014-02-554071.
33. Shain K.H., Yarde D.N., Meads M.B., et al. Beta 1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res 2009, 69:1009-1015. 10.1158/0008-5472.CAN-08-2419.